Downregulation of Mucin1 in Cancer Cells is Associated with Modulation of Calcium Signalling Pathways and Alteration in Procoagulant Related Activity Mucin1 effect on calcium pathway and procoagulant activity in cancer cells

Article Sidebar

PDF Download
Published Jun 26, 2023
DOI: https://doi.org/10.18103/mra.v11i6.3890

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

yunliang chen
Molecular Coagulation Biology Lab Thrombosis Research Institute Emmanuel Kaye Building 1b Manresa Road London UK SW3 6LR
Michael Scully
Molecular Coagulation Biology Lab Thrombosis Research Institute Emmanuel Kaye Building 1b Manresa Road London UK SW3 6LR

Abstract

Background Intracellular calcium ions play an essential role in regulating numerous physiological functions by acting as a second messenger in signal transduction pathways. Alterations in calcium signaling are also implicated in several pathological conditions including cancer.


Aim The purpose of this study is to investigate whether MUC1, a well-established tumor marker, plays a role in modulating calcium signalling in cancer cells.


Methods MUC1 knockdown breast cancer MCF-7 cells were used to investigate whether the overexpression of MUC1 by cancer cells has an influence on calcium signalling pathways, by determining the level of a range of calcium signalling proteins and the dynamics of intracellular calcium mobilization as well as the cellular effects induced by calcium treatment. The investigation was also extended to normal human mammary epithelial, human breast and pancreatic cancer cell lines, which express different levels of MUC1.


Result MUC1 downregulation altered the aberrant expression of several calcium transporter proteins in MCF-7 cancer cells. The level of each of these calcium signaling pathways proteins was correlated to MUC1 level in normal human mammary epithelial, human breast and pancreatic cancer cell lines. Consequently, a number of proteins whose activities are calcium dependent such as p-CaMKII, and pro-coagulant proteins Va, Xa and thrombin were found to be reduced in MUC1 downregulated MCF-7 cells. In addition, the effect of thrombin on calcium mobilization and the cleavage of the thrombin receptors was also reduced in MUC1 downregulated MCF-7 cells.


Conclusion The downregulation of MUC1 is capable of modulating calcium cellular effects via alteration in the expression of calcium signalling proteins and by impacting calcium induced initiation of procoagulant activity, which is capable of influencing the effect of thrombin on cancer cells. Such properties contribute to another crucial role for MUC1 within the signalling network associated with tumorigenesis.

Keywords: Mucin1, calcium signalling, coagulation, breast and pancreatic cancer

Article Details

How to Cite
CHEN, yunliang; SCULLY, Michael. Downregulation of Mucin1 in Cancer Cells is Associated with Modulation of Calcium Signalling Pathways and Alteration in Procoagulant Related Activity. Medical Research Archives, [S.l.], v. 11, n. 6, june 2023. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3890>. Date accessed: 15 may 2024. doi: https://doi.org/10.18103/mra.v11i6.3890.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 11 No 6 (2023): June Issue, Vol.11, Issue 6
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Stewart TA, Yapa KT, Monteith GR. Altered calcium signaling in cancer cells. Biochim Biophys Acta. 2015; 1848(10 Pt B):2502-11.
2. Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta Pharm Sin B. 2017; 7(1):3-17.
3. Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer. 2011; 11(8):609-18.
4. Prevarskaya N, Skryma R, Shuba Y.Ion. Channels in Cancer: Are Cancer Hallmarks Oncochannelopathies? Physiol Rev. 2018; 98(2):559-621.
5. Maklad A, Sharma A, Azimi I. Calcium Signaling in Brain Cancers: Roles and Therapeutic Targeting. Cancers (Basel). 2019;11(2):145.
6. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9:874–885.
7. Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 2014; 20:332–342.
8. Horm TM, Schroeder JA. MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh Migr. 2013 7(2):187-98.
9. Rahn JJ, Shen Q, Mah BK, Hugh JC. MUC1 Initiates a Calcium Signal after Ligation by Intercellular Adhesion Molecule-1. J Biol. Chem 2004; 279 (28):29386–29390.
10. Guang W, Kim KC, Lillehoj EP. MUC1 mucin interacts with calcium-modulating cyclophilin ligand. Int J Biochem Cell Biol. 2009; 41(6):1354-60.
11. Sheth RA, Niekamp A, Quencer KB, Shamoun F, Knuttinen MG, Naidu S, Oklu R. Thrombosis in cancer patients: etiology, incidence, and management. Cardiovasc Diagn Ther. 2017;7(Suppl 3): S178-S185. doi: 10.21037/cdt.2017.11.02.
12. Chen Y, Scully M..Tumour-associated Mucin1 correlates with the procoagulant properties of cancer cells of epithelial origin. 2022; 9:100123. doi.org/10.1016/j.tru.2022.100123
13. Chen Y, Scully M, Dawson G, Goodwin C, Xia M, Lu X, Kakkar A. Perturbation of the heparin/heparin-sulfate interactome of human breast cancercells modulates pro- tumorigenic effects associated with PI3K/Akt and MAPK/ERK signalling. Thromb Haemost. 2013; 109(6):1148-57.
14. N. Cao, X. B. Chen and D. J. Schreyer. Influence of Calcium Ions on Cell Survival and Proliferation in the Context of an Alginate Hydrogel. International Scholarly Research Network (ISRN) Chemical Engineering Volume 2012; doi:10.5402/2012/516461
15. Ghavimi SAA, Allen BN, Stromsdorfer JL, Kramer JS, Li X, Ulery BD. Calcium and phosphate ions as simple signaling molecules with versatile osteoinductivity. Biomed Mater. 2018;13(5):055005. doi: 10.1088/1748-605X/aac7a5.
16. Bates SM, Weitz JI. Coagulation assays. Circulation 2005;112:e53-60.
17. Chi M, Evans H, Gilchrist J, Mayhew J, Hoffman A, Pearsall EA, et al. Phosphorylation of calcium/calmodulin-stimulated protein kinase II at T286enhances invasion and migration of human breast cancer cells. Sci Rep. 2016 6:33132.
18. Lee WJ, Roberts-Thomson SJ, Monteith GR, Plasma membrane calcium-ATPase 2 and 4 in human breast cancer cell lines, Biochem. Biophys. Res. Commun. 337 (2005) 779–783.
19. Varga K, Pászty K, Padányi R, Hegedűs L, Brouland JP, Papp B, et al. Histone deacetylase inhibitor- and PMA-induced upregulation of PMCA4b enhances Ca2+ clearance from MCF-7 breast cancer cells. Cell Calcium 2014; 55: 78–92.
20. RibiczeyP, Tordai A, Andrikovics H, Filoteo AG, Penniston JT, Enouf J, et al. Isoform-specific up-regulation of plasma membrane Ca2+ ATPase expression during colon and gastric cancer cell differentiation. Cell Calcium 2007; 42: 590–605.
21. Arbabian A, Brouland JP, Gelebart P, Kovacs T, Bobe R, Enouf J, et al. Endoplasmic reticulum calcium pumps and cancer. BioFactors. 2011; 37:139–149.
22. Denmeade SR, Isaacs JT. The SERCA pump as a therapeutic target: making a “smart bomb” for prostate cancer. Cancer Biol.Therap. 2005; 4:14–22.
23. Chung FY, Lin SR, Lu CY, Yeh CS, Chen FM, Hsieh JS, et al. Sarco/endoplasmic reticulum calcium-ATPase 2 expression as a tumor marker in colorectal cancer. The Am.J.Surg.Pathol. 2006; 30:969–974.
24. Roti G, Carlton A, Ross KN, Markstein M, Pajcini K, Su AH, et al. Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. Cancer Cell. 2013; 23:390–405.
25. Berna-Erro A, Woodard GE, Rosado JA. Orais and STIMs: physiological mechanisms and disease, J. Cell. Mol. Med. 2012; 16: 407–424.
26. Shaw PJ, Feske S. Physiological and pathophysiological functions of SOCE in the immune system. Front Biosci (Elite Ed). 2012; 4:2253-68.
27. Soboloff J, Rothberg BS, Madesh M, Gill DL. STIM proteins: dynamic calcium signal transducers. Nat Rev Mol Cell Biol. 2012; 13:549–65.
28. Roberts-Thomson SJ, Curry MC, Monteith GR. Plasma membrane calcium pumps and their emerging roles in cancer. World J Biol Chem. 2010; 1(8):248-53.
29. Griffith LC. Regulation of calcium/ calmodulin-dependent protein kinase II activation by intramolecular and intermolecular interactions. J Neurosci. 2004; 24(39):8394-8.
30. Le Bonniec BF, Guinto ER, Esmon CT. The role of calcium ions in factor X activation by thrombin E192Q. J Biol Chem. 1992; 267(10):6970-6.
31. Li Z, Li X, McCracken B, Shao Y, Ward K, Fu J. A Miniaturized Hemoretractometer for Blood Clot Retraction Testing. Small. 2016; 12(29):3926-34.
32. Rabiet MJ, Plantier JL, Dejana E Thrombin-induced endothelial cell dysfunction. Br Med Bull. 1994; 50(4):936-45.
33. Ishii K, Gerszten R, Zheng YW, Welsh JB, Turck CW, Coughlin SR. Determinants of thrombin receptor cleavage. Receptor domains involved, specificity, and role of the P3 aspartate. J Biol Chem. 1995; 270(27):16435-40.
34. Tanaka N, Morita T, Nezu A, Tanimura A, Mizoguchi I, Tojyo Y. Thrombin-induced Ca2+ mobilization in human gingival fibroblasts is mediated by protease-activated receptor-1 (PAR-1). Life Sci. 2003; 73(3):301-10.
35. Jones CA and Hazlehurst LA. Role of Calcium Homeostasis in Modulating EMT in Cancer. Biomedicines. 2021;9(9):1200. doi: 10.3390/biomedicines9091200
36. Wang YY, Zhao R, Zhe H. The emerging role of CaMKII in cancer. Oncotarget. 2015; 6(14):11725–11734.
37. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol. 2006; 26(3):456-61.